Abstract
Background and Objectives: It is generally accepted that inflammatory cells found in the tumor microenvironment are involved in the neoplastic process, promoting cell proliferation, survival, and migration. Therefore, administering anti-inflammatory medication in cancer therapy seems to be justified. A potential pathway associated with the aforementioned issue is cyclooxygenase-2 inhibition, particularly as the overexpression of this enzyme has been proven to occur in cancer tissues and is also associated with a poor prognosis in several types of human malignancies. Celecoxib, a COX-2 selective inhibitor, has been utilized for over 20 years, particularly as an anti-inflammatory, analgesic and antipyretic medication. However, to date, its antineoplastic properties have not been sufficiently investigated. In recent years, the number of research studies on the antineoplastic effects of celecoxib has increased considerably. The vast majority of publications refers to preclinical studies attempting to elucidate its mechanisms of action. Clinical trials concerning celecoxib have focused primarily on the treatment of cancers of the colon, breast, lung, prostate, stomach, head and neck, as well as premalignant lesions such as familial adenoma polyposis. In this review article authors attempt to summarise the latest research which has elucidated celecoxib use in the treatment and prevention of cancer.
Conclusion: Both preclinical and clinical studies have demonstrated promising results of the role of celecoxib in the treatment and prevention of cancer – the best outcome was observed in colon, breast, prostate and head and neck cancers. However, more clinical trials providing real evidence-based clinical advances of celecoxib use are needed.
Keywords: Cancer, celecoxib, chemotherapy of cancer, combination therapy, COX-2, inflammation.
Graphical Abstract
[2]
Conaghan PG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012; 32: 1491-502.
[3]
Harris RE, Beebe J, Alshafie GA. Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. J Exp Pharmacol 2012; 4: 91-6.
[4]
Fujii R, Imanishi Y, Shibata K, et al. Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Exp Clin Cancer Res 2014; 33: 40.
[5]
Sacchetti A. Cancer cell killing by Celecoxib: Reality or just in vitro precipitation-related artifact? J Cell Biochem 2013; 114: 1434-44.
[6]
Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacol 2007; 15: 1-4.
[7]
Chow LW, Loo WT, Yip AY, Ng EL. Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: A subanalysis of biomarkers for cardiac injury. Int J Biol Markers 2013; 28: 92-9.
[8]
Xu HB, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. Eur J Pharmacol 2016; 776: 1-8.
[9]
Benson P, Yudd M, Sims D, et al. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin Nephrol 2012; 78: 376-81.
[10]
Mohsen V, Mohsen A. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014; 9: 255-67.
[11]
Mathew ST, Devi SG, Prasanth VV, Vinod B. Efficacy and safety of cox-2 inhibitors in the clinical management of arthritis: Mini Review. ISRN Pharmacol 2011; 2011: 480291.
[12]
Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64: 233-52.
[13]
Ye Y, Liu M, Yuan H, et al. COX-2 regulates Snail expression in gastric cancer via the Notch1 signaling pathway. Int J Mol Med 2017; 40: 512-22.
[14]
Ghanghas P, Jain S, Rana C, Sanyal SN. Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. Biomed Pharmacother 2016; 78: 239-47.
[15]
Xiang HG, Xie X, Hu FQ, et al. Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma. Oncol Rep 2014; 32: 1140-8.
[16]
Egashira I, Takahashi-Yanaga F, Nishida R, et al. Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. Cancer Sci 2017; 108: 108-15.
[17]
Ninomiya I, Nagai N, Oyama K, et al. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep 2012; 28: 777-84.
[18]
Garcia M, Velez R, Romagosa C, et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014; 113: E164-77.
[19]
Goswami S, Sharma-Walia N. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: Implications in carcinogenesis. Oncotarget 2016; 7: 58953-74.
[20]
Campillo N, Torres M, Vilaseca A, et al. Role of cyclooxygenase-2 on intermittent hypoxia-induced lung tumor malignancy in a mouse model of sleep apnea. Sci Rep 2017; 7: 44693.
[21]
Kido LA, Montico F, Vendramini-Costa DB, Pilli RA, Cagnon VH. Goniothalamin and celecoxib effects during aging: Targeting Pro-inflammatory mediators in chemoprevention of prostatic disorders. Prostate 2017; 77: 838-.
[22]
Dai ZJ, Ma XB, Kang HF, et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo/in vitro and in vivo. Cancer Cell Int 2012; 12: 53.
[23]
Rosas C, Sinning M, Ferreira A, Fuenzalida M, Lemus D. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol Res 2014; 47: 27.
[24]
Ghanghas P, Jain S, Rana C, Sanyal SN. Chemoprevention of colon cancer through inhibition of angiogenesis and induction of apoptosis by nonsteroidal anti-inflammatory drugs. J Environ Pathol Toxicol Oncol 2016; 35: 273-89.
[25]
Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013; 332: 313-24.
[26]
Ramer R, Walther U, Borchert P, et al. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res 2013; 54: 3116-29.
[27]
Li WW, Long GX, Liu DB, et al. Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Pharmazie 2014; 69: 132-7.
[28]
Xu B, Wang Y, Yang J, et al. Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo. Cancer Chemother Pharmacol 2016; 77: 797-806.
[29]
Chiang SL, Velmurugan BK, Chung CM, et al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep 2017; 7: 6235.
[30]
Garg M. Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer. World J Stem Cells 2013; 5: 188-95.
[31]
Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013; 34: 638-46.
[32]
Lönnroth C, Andersson M, Arvidsson A, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8: 5.
[33]
Lönnroth C, Andersson M, Asting AG, Nordgren S, Lundholm K. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol 2014; 45: 2208-20.
[34]
Schellhorn M, Haustein M, Frank M, Linnebacher M, Hinz B. Celecoxib increases lung cancer cell lysis by lymphokine activated killer cells via upregulation of ICAM-1. Oncotarget 2015; 6: 39342-56.
[35]
Paznekas WA, Okajima K, Schertzer M, Wood S, Jabs EW. Genomic organization, expression, and chromosome location of the human SNAIL gene (SNAI1) and a related processed pseudogene (SNAI1P). Genomics 1999; 62: 42-9.
[36]
Saito Y, Suzuki H, Imaeda H, et al. The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer 2013; 132: 1751-60.
[37]
Abrahão AC, Giudice FS, Sperandio FF, Pinto Junior Ddos S. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J Oral Pathol Med 2013; 42: 793-8.
[38]
Liu M, Li CM, Chen ZF, et al. Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Int J Mol Med 2014; 33: 1451-8.
[39]
Liu DB, Hu GY, Long GX, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin 2012; 33: 682-90.
[41]
Saha B, Adhikary A, Ray P, et al. Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells. Oncogene 2012; 31: 173-86.
[42]
Liu HF, Hsiao PW, Chao JI. Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem Biol Interact 2008; 176: 48-57.
[43]
Katkoori VR, Manne K, Vital-Reyes VS, et al. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem 2013; 88: 38-46.
[44]
Zhu X, Zhou M, Liu G, et al. Autophagy activated by the c Jun N terminal kinase mediated pathway protects human prostate cancer PC3 cells from celecoxib induced apoptosis. Exp Ther Med 2017; 13: 2348-54.
[45]
Kashiwagi E, Shiota M, Yokomizo A, et al. EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 10-7.
[46]
Brizzolara A, Benelli R, Venè R, et al. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Cancer Lett 2017; 400: 9-17.
[47]
Esbona K, Inman D, Saha S, et al. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res 2016; 18: 35.
[48]
Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev 2015; 2015: 536962.
[49]
Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007; 5: 19-34.
[50]
Gong L, Thorn CF, Bertagnolli MM, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012; 22: 310-8.
[51]
Patrono C. Cardiovascular effects of cyclooxygenase‐2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016; 82: 957-64.
[52]
Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther 2014; 36: 1253-63.
[53]
Thompson PA, Ashbeck EL, Roe DJ, et al. Celecoxib for the prevention of colorectal adenomas: Results of a suspended randomized controlled trial. J Natl Cancer Inst 2016; 108: djw151.
[54]
Wang LW, Hsiao CF, Chen WT, et al. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study. J Surg Oncol 2014; 109: 580-5.
[55]
James ND, Sydes MR, Mason MD, et al. STAMPEDE Investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial. Lancet Oncol 2013; 14: e5.
[56]
Perroud HA, Alasino CM, Rico MJ, et al. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: Clinical outcomes and biomarkers of response. Cancer Chemother Pharmacol 2016; 77: 365-74.
[57]
Varga Z, Sabzwari S, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: An under-recognized public health issue. Cureus 2017; 9: e1144.
[59]
Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8: 173-82.
[60]
Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26: 285-91.
[61]
Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective nsaids on hospitalization for acute kidney injury. A nested case-control cohort study. Medicine (Baltimore) 2016; 95: e2645.
[62]
Benson P, Yudd M, Sims D, et al. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin Nephrol 2012; 78: 376-81.
[63]
Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 2017; 18: 256.
[64]
Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25: 537-44.
[65]
Lee Y, Kim H, Kim W, et al. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. J Drug Target 2012; 20: 524-34.
[66]
Gowda R, Kardos G, Sharma A, Singh S, Robertson GP. Nanoparticle-based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. Mol Cancer Ther 2017; 16: 440-52.
[67]
Allhenn D, Neumann D, Béduneau A, Pellequer Y, Lamprecht AA. “drug cocktail” delivered by microspheres for the local treatment of rat glioblastoma. J Microencapsul 2013; 30: 667-73.
[68]
Fakih MG, Rustum YM. Does celecoxib have a role in the treatment of patients with colorectal cancer? Clin Colorectal Cancer 2009; 8: 11-4.
[69]
No authors listed. Celecoxib: new indication. Colorectal cancer: No preventive benefit. Prescrire Int 2006; 15: 13-5.
[70]
Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
[71]
Solomon SD, McMurray JJ, et al. For the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005; 352: 1071-80.
[72]
Manzano A, P’erez-Segura P. Colorectal cancer chemoprevention: Is this the future of colorectal cancer prevention? Sci World J 2012; 2012: 327341.
[73]
Wang Y, Zhang FC, Wang YJ. The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: A meta-analysis and systematic review of randomized trials. Colorectal Dis 2015; 17: 188-96.
[74]
Veettil SK, Teerawattanapong N, Ching SM, et al. Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials. OncoTargets Ther 2017; 10: 2689-700.
[75]
Falandry C, Debled M, Bachelot T, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: A double-blind phase III GINECO study. Breast Cancer Res Treat 2009; 116: 501-8.
[77]
Perroud HA, Rico MJ, Alasino CM, et al. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 2013; 9: 451-62.
[78]
Brandão RD, Veeck J, Van de Vijver KK, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013; 15: R29.
[79]
Liao Z, Komaki R, Milas L, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005; 11: 3342-8.
[80]
Arúajo AM, Mendez JC, Coelho AL, et al. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 2009; 27: 391-6.
[81]
Gore E. Celecoxib and radiation therapy in non-small-cell lung cancer. Oncology 2004; 18: 10-4.
[82]
Koch A, Bergman B, Holmberg E, et al. Swedish Lung Cancer Study Group Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011; 47: 1546-55.
[83]
Edelman MJ, Wang X, Hodgson L, et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J Clin Oncol 2017; 35: 2184-92.
[84]
Reckamp KL, Koczywas M, Cristea MC, et al. Randomized phase ii trial of erlotinib in combination with high dose-celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 2015; 121: 3298-306.
[85]
Sooriakumaran P, Coley HM, Fox SB, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009; 29: 1483-8.
[86]
Smith MR, Manola J, Kaufman DS, et al. Celecoxib Versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723-8.
[87]
Mason MD, Clarke NW, James ND, et al. STAMPEDE investigators Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol 2017; 35: 1530-41.
[88]
Kattan J, Bachour M, Farhat F, et al. Phase II trial of weekly docetaxel, zoledronic acid, and celecoxib for castration-resistant prostate cancer. Invest New Drugs 2016; 34: 474-80.
[89]
Jeong Y, Lee JL. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer. Asia Pac J Clin Oncol 2017; 13: 204-11.
[90]
Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacol 2007; 15: 1-4.
[91]
Wang Z, Chen JQ, Liu JL. COX-2 Inhibitors and Gastric Cancer. Gastroenterol Res Pract 2014; 2014: 132320.
[92]
Han X, Li H, Su L, et al. Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer. Biomed Rep 2014; 2: 183-7.
[93]
Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61: 812-8.
[94]
Rhee JC, Khuri FR, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist 2004; 9(3): 302-11.
[95]
Gupta B, Johnson NW, Kumar N. Global epidemiology of head and neck cancers: A continuing challenge. Oncology 2016; 91: 13-3.
[96]
Lee DY, Lim JH, Kim YJ, et al. Effect of celecoxib on survival of mobile tongue cancer. Anticancer Res 2015; 35: 4235-41.
[97]
Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015; 51: 279-86.
[98]
Patil VM, Chakraborty S, Jithin TK, et al. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. South Asian J Cancer 2016; 5: 48-51.
[99]
Patil VM, Noronha V, Joshi A, et al. Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian J Med Paediatr Oncol 2015; 36: 161-5.
[100]
Lodi G, Franchini R, Warnakulasuriya S, et al. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev 2016; 7: CD001829.
[101]
Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) 2014; 7: 283-91.
[102]
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) Prodrugs. Chem Rev 2016; 116: 3436-86.
[103]
Xu HB, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2. Eur J Pharmacol 2015; 769: 1-7.
[104]
Shi L, Zhong D, Gu C, Yu L. Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 2014; 34(6): 792-7.
[105]
Chen M, Yu L, Gu C, et al. Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Lett 2013; 329: 189-96.
[106]
Álvarez P, Marchal JA, Boulaiz H, et al. 5-Fluorouracil derivatives: A patent review. Expert Opin Ther Pat 2012; 22: 107-23.
[107]
Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 2007; 59: 839-45.
[108]
He J, Pei L, Jiang H, et al. Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation. J Cancer 2017; 8: 1187-96.
[109]
Rahman M, Selvarajan K, Hasan MR, et al. Inhibition of COX-2 in colon cancer modulates tumor growth and mdr-1 expression to enhance tumor regression in therapy-refractory cancers In vivo. Neoplasia 2012; 14: 624-33.
[110]
Zhang XQ, Sun XE, Liu WD, et al. Synergic effect between 5 fluorouracil and celecoxib on hypoxic gastric cancer cells. Mol Med Rep 2015; 11: 1160-6.
[111]
Zhang XQ, Zhang HM, Sun XE, Yuan ZJ, Feng YG. Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med 2015; 9: 105-11.
[112]
Sung MW, Lee DY, Park SW, et al. Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. Laryngoscope 2017; 127: E117-23.
[113]
Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005; 27: 684-94.
[114]
Qian M, Qian D, Jing H, et al. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep 2014; 32: 1681-8.
[115]
Valverde A, Peñarando J, Cañas A, et al. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. Oncotarget 2017; 8: 21754-69.
[116]
Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin B 2011; 1: 197-207.
[117]
Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013; 19: 1244-56.
[118]
Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. Cell Mol Biol (Noisy-le-grand) 2016; 62: 68-74.
[119]
Valverde A, Peñarando J, Cañas A, et al. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLoS One 2015; 10: e0131363.
[120]
Maji S, Samal SK, Pattanaik L, et al. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 2015; 6: 16623-37.
[121]
Patil VM, Noronh V, Joshi A, et al. Metronomic palliative chemotherapy in maxillary sinus tumor. South Asian J Cancer 2016; 5: 56-8.
[122]
Janakiraman H, House RP, Talwar S, et al. Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene 2016; 36: 3137-48.
[123]
Kumar BN, Rajput S, Dey KK, et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013; 13: 273.
[124]
Cheki M, Yahyapour R, Farhood B, et al. COX-2 in Radiotherapy; a potential target for radioprotection and radiosensitization. Curr Mol Pharmacol 2018; 11(3): 173-83.
[125]
Zhang SX, Qiu QH, Chen WB, Liang CH, Huang B. Celecoxib enhances radiosensitivity via induction of G2-M phase arrest and apoptosis in nasopharyngeal carcinoma. Cell Physiol Biochem 2014; 33: 1484-97.
[126]
Yusup G, Akutsu Y, Mutallip M, et al. Matsubara H. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int J Oncol 2014; 44: 1146-52.
[127]
Han ZQ, Liao H, Shi F, et al. Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis. Oncol Lett 2017; 14(5): 5959-65.
[128]
Yang J, Yue JB, Liu J, et al. Effect of celecoxib on inhibiting tumor repopulation during radiotherapy in human FaDu squamous cell carcinoma. Contemp Oncol (Pozn) 2014; 18: 260-7.
[129]
Xu XT, Hu WT, Zhou JY, Tu Y. Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP. Am J Transl Res 2017; 9: 1088-100.
[130]
Kim YM, Jeong IH, Pyo H. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines. Int J Radiat Oncol Biol Phys 2012; 83: e399-407.
[131]
Pal I, Dey KK, Chaurasia M, et al. Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour Biol 2016; 37: 6389-402.
Article Metrics
136
14